Bank recommends selling Moderna after 600% rally

A U.S. bank has issued a sell recommendation on Moderna after its stock surged nearly 600% this year, signaling a potential valuation peak. The recommendation reflects growing caution about the sustainability of the rally, likely driven by vaccine-related catalysts. This marks a notable shift in sentiment, as the bank had previously been more positive or neutral.